Aligos Therapeutics, Inc. (ALGS) has a negative trailing P/E of -3.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -29.22%, forward earnings yield 33.44%. PEG 0.04 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -564.1 | 0.00 | -571.70 | 0.00 | - |
| 2019 | -155.8 | -0.60 | -125.47 | 0.00 | - |
| 2020 | -217.7 | -6.48 | 107.37 | 0.00 | - |
| 2021 | -92.2 | -73.27 | 64.02 | 2,713.26 | - |
| 2022 | -10.6 | 0.35 | 9.79 | 73.13 | - |
| 2023 | -4.7 | -0.08 | 4.48 | 26.59 | - |
| 2024 | -1.9 | 0.00 | -8.61 | 63.27 | - |
| 2025 | -3.8 | 0.04 | 1.72 | 42.14 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.66 | $0.00 | $-13.93M | - |
| 2019 | $-2.38 | $0.00 | $-52.26M | - |
| 2020 | $-3.18 | $0.00 | $-108.54M | - |
| 2021 | $-3.22 | $4.36M | $-128.33M | -2944.1% |
| 2022 | $-2.25 | $13.91M | $-96.05M | -690.6% |
| 2023 | $-3.52 | $15.53M | $-87.68M | -564.6% |
| 2024 | $-20.94 | $3.95M | $-131.21M | -3326% |
| 2025 | $-2.45 | $2.19M | $-24.19M | -1106.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-6.67 | $-6.95 – $-6.39 | $1.42M | $1.42M – $1.42M | 3 |
| 2027 | $-4.95 | $-6.45 – $-3.45 | $1.78M | $1.78M – $1.78M | 3 |
| 2028 | $-1.68 | $-5.66 – $9.08 | $69.03M | $69.03M – $69.03M | 4 |
| 2029 | $2.86 | $2.86 – $2.86 | $191.97M | $191.97M – $191.97M | 2 |
| 2030 | $5.23 | $5.23 – $5.23 | $334.88M | $334.88M – $334.88M | 2 |
